Incyte (NASDAQ: INCY) announced that The New England Journal of Medicine (NEJM) published results from the pivotal Phase III RESPONSE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE